生命科学资讯

IO mulls more layoffs months after halving head count in wake of cancer vaccine setback

Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery

Cancer imaging company buys Lisata for phase 2-stage solid tumor drug

Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat

Worldwide Clinical Trials adds Catalyst Clinical to global CRO mixture

Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever

Former Spero execs fined by SEC over antibiotic efficacy claims

Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years

Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs

Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis

Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs

GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair

ARPA-H director eyes future beyond vaccines, ‘winning the biotech race’ against China

Abbott, AtaCor join forces on extravascular defibrillator implant

FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions

AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta

Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions

Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program

Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO